GenePlanet, a pioneer in genetic testing solutions, is excited to announce the launch of the pharmacogenomic test MyMeds, a cutting-edge medical device that redefines personalised medicine. Developed by an in-house R&D team, MyMeds empowers individuals and healthcare professionals to optimise medication choices based on unique genetic makeup. 

More than 99% of people have gene variants affecting how they respond to medication. Understanding that one size does not fit all when it comes to medication, pharmacogenomics (or shortly PGx) reveals how an individual’s genes influence their response to various drugs.  

With MyMeds – a simple saliva-based test – patients and their healthcare providers gain invaluable insights to streamline treatment, minimise side effects, and enhance overall therapeutic outcomes.  

The power of PGx test 

Utilising pharmacogenomics allows doctors to move away from the current “one drug and one dose fits all” to a more personalised approach, which improves the safety and effectiveness of medicine. 

MyMeds allows healthcare professionals to identify the most suitable drugs and dose from the beginning, based on patients’ genetic makeup. This minimises patient suffering and expedites relief. 

Such contribution to more effective and personalised healthcare outcomes marks a pivotal shift towards precision medicine. 

“MyMeds test revolutionises personalised medicine, as it reduces the cost of treatment by reducing adverse drug reaction costs,” explains GenePlanet’s CEO Marko Bitenc. “This is a huge problem globally. For example, annually, these reactions lead to 197,000 deaths in Europe and cost €343 million in Germany alone. MyMeds enhances treatment efficiency, offering a cost-effective approach, especially in high-cost fields like cardiology, oncology, and psychiatry. This innovation prioritises individual well-being and economic sustainability in healthcare.” 

Competitive advantages of MyMeds test 

• Utilises the latest technologies and clinical standards: 

MyMeds is meticulously crafted with state-of-the-art technologies and adheres to the highest clinical standards, ensuring accuracy, reliability, and actionable insights. Powered by advanced algorithms and whole genome sequencing, it provides precise genotyping of relevant genome regions in pharmacogenomics, offering unparalleled depth of understanding. 

• Seamless integration with clinical practice: 

In addition to genetic results, MyMeds seamlessly provides partner healthcare providers with comprehensive clinical guidelines through an intuitive application. This streamlines decision-making, allowing for more informed and personalised patient care. 

• Comprehensive test with lifetime value 

MyMeds encompasses recommendations for medications across 15 different medical specialities, including cardiology, oncology, neurology, pain therapy, psychiatry, and more. With the power of whole genome sequencing (WGS), MyMeds adapts to scientific advancements, incorporating new genetic variants affecting medication response, all without the need for additional sampling or costs. 

MyMeds is set to empower both healthcare professionals and individuals, making informed choices for better health outcomes more accessible than ever before. By unlocking the power of genetics, MyMeds offers a new era of healthcare that prioritises individual needs and preferences. 

For more information about PGx test MyMeds, visit https://geneplanet.com/my-meds or write to [email protected], and join us in embracing a future of personalised medicine.